Chilton Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Chilton Capital Management’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-39	Closed	-$1.79K	–	572
2025 Q2	$1.79K	Hold	39	–	–	﹤0.01%	504
2025 Q1	$1.88K	Buy	+39	New	+$2.09K	﹤0.01%	505

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return

Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Chilton Capital Management's BIB Position: Q3 2025 in Review

Chilton Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2025, closing a stake of 39 shares — an estimated $1.79K sold.

Chilton Capital Management first reported a position in BIB in Q1 2025 and held it in 2 quarters. The position peaked at $1.88K in Q1 2025. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2025.

Chilton Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2025 after selling out during the quarter.
Chilton Capital Management sold 39 ProShares Ultra NASDAQ Biotechnology shares in Q3 2025, an estimated $1.79K.
Chilton Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2025 and held it in 2 quarters.
Chilton Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $1.88K in Q1 2025.
19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2025.

Based on Chilton Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.